Molecular Assemblies, Inc. announced that it has received funding from Codexis, Inc., Casdin Capital, LLC, Lyfe Capital, Argonautic Ventures, iSelect Fund Management, LLC, Agilent Technologies, Inc. and other investors
September 25, 2022
Share
On September 26, 2022, Molecular Assemblies, Inc. closed the transaction. The company raised $146,575 in its third tranche closing, bringing the total gross proceeds raised in the transaction to $25,946,575. The transaction included participation form 14 investors.
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Molecular Assemblies, Inc. announced that it has received funding from Codexis, Inc., Casdin Capital, LLC, Lyfe Capital, Argonautic Ventures, iSelect Fund Management, LLC, Agilent Technologies, Inc. and other investors
CODEXIS, INC. 
